- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hikma Pharmaceuticals PLC (HIK)
Hikma Pharmaceuticals PLC stock price live, this page displays LON HIK stock exchange data. View the HIK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Hikma Pharmaceuticals PLC real time stock price chart below.
What Is the Hikma Pharmaceuticals PLC Stock Price Today?
The Hikma Pharmaceuticals PLC stock price today is 1,640.00.
What Is the Stock Symbol for Hikma Pharmaceuticals PLC?
The stock symbol for Hikma Pharmaceuticals PLC is "HIK."
What Stock Exchange Does Hikma Pharmaceuticals PLC Trade On?
Hikma Pharmaceuticals PLC is listed and trades on the London stock exchange.
Is Hikma Pharmaceuticals PLC a Good Stock to Buy?
Determining whether Hikma Pharmaceuticals PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HIK quote. (ISIN: GB00B0LCW083)
What Is the Hikma Pharmaceuticals PLC Stock Price Today?
The Hikma Pharmaceuticals PLC stock price today is 1,640.00.
What Is the Stock Symbol for Hikma Pharmaceuticals PLC?
The stock symbol for Hikma Pharmaceuticals PLC is "HIK."
What Stock Exchange Does Hikma Pharmaceuticals PLC Trade On?
Hikma Pharmaceuticals PLC is listed and trades on the London stock exchange.
Is Hikma Pharmaceuticals PLC a Good Stock to Buy?
Determining whether Hikma Pharmaceuticals PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HIK quote. (ISIN: GB00B0LCW083)
London
Currency in GBP
1,640.00
-3.00(-0.18%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,622.00
1,654.00
52 wk Range
1,187.00
1,865.00
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,622.001,654.00
52 wk Range
1,187.001,865.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.87%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.87%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
HIK Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
1,892.89
Upside
+15.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 10 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Analyst Ratings
11 Buy
0 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 1,892.89
(+15.42% Upside)
Hikma Pharmaceuticals PLC Earnings Call Summary for H1/2026
- Hikma reported H1 2026 revenue up 4% YoY, EBIT and EBITDA up 8%, EPS up 5%; shares surged 9.9% to $1,726.5 on the results.
- Full-year guidance unchanged at GBP 720-770M operating profit despite strong H1, citing planned H2 increases in R&D, promotion, and hiring spend.
- MENA division led growth with tender deliveries and regional stockpiling; injectables stabilized with TYZAVAN adoption improving and new Bedford plant due 2028.
- Company divesting loss-making 503B compounding business within 12 months; reduced slow-moving inventory to GBP 40M from GBP 90M year-earlier.
- Management expects H2 MENA normalization after stockpiling, TYZAVAN acceleration in Q4, and increased injectable submissions to drive growth from 2028 onward.
Last Updated: 2026-08-06, 05:32 a/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
1.02 / --
Revenue / Forecast
1.73B / --
Compare HIK to Peers and Sector
Metrics to compare | HIK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHIKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.0x | 23.5x | −0.4x | |
PEG Ratio | 2.25 | −0.10 | 0.00 | |
Price/Book | 1.8x | 2.1x | 2.6x | |
Price / LTM Sales | 1.4x | 2.8x | 3.1x | |
Upside (Analyst Target) | 14.4% | 5.3% | 48.4% | |
Fair Value Upside | Unlock | 15.1% | 6.5% | Unlock |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Hikma Pharma (HIK) Stock Price Today?
The Hikma Pharma stock price today is 1,640.00 GBP.
What Stock Exchange Does Hikma Pharma Trade On?
Hikma Pharma is listed and trades on the London Stock Exchange.
What Is the Stock Symbol for Hikma Pharma?
The stock symbol for Hikma Pharma is "HIK."
Does Hikma Pharma Pay Dividends? What’s The Current Dividend Yield?
The Hikma Pharma dividend yield is 3.87%.
What Is the Hikma Pharma Market Cap?
As of today, Hikma Pharma market cap is 3.46B GBP.
What Is Hikma Pharma's Earnings Per Share (TTM)?
The Hikma Pharma EPS (TTM) is 1.76.
From a Technical Analysis Perspective, Is HIK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Hikma Pharma Stock Split?
Hikma Pharma has split 0 times.
How Many Employees Does Hikma Pharma Have?
Hikma Pharma has 9500 employees.
What is the current trading status of Hikma Pharma (HIK)?
As of Aug 14, 2026, Hikma Pharma (HIK) is trading at a price of 1,640.00 GBP, with a previous close of 1,643.00 GBP. The stock has fluctuated within a day range of 1,622.00 GBP to 1,654.00 GBP, while its 52-week range spans from 1,187.00 GBP to 1,865.00 GBP.
What Is Hikma Pharma (HIK) Price Target According to Analysts?
The average 12-month price target for Hikma Pharma is 1,892.89 GBP, with a high estimate of 2618.37493519 GBP and a low estimate of 1319.53188653 GBP. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +15.42% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.